A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis
Latest Information Update: 21 Feb 2025
At a glance
- Drugs ANB 032 (Primary)
- Indications Atopic dermatitis
- Focus Proof of concept; Therapeutic Use
- Acronyms ARISE-AD
- Sponsors AnaptysBio
Most Recent Events
- 14 Feb 2025 Status changed from active, no longer recruiting to discontinued.because ANB032 did not meet the primary endpoint in moderate-to-severe atopic dermatitis .
- 11 Dec 2024 Primary endpoint (Proportion of subjects who achieve 75% reduction (improvement) from Baseline in EASI-75 as Week 14) has not been met, according to an AnaptysBio media release.
- 14 Aug 2024 According to an AnaptysBio media release, company announced the pricing of an underwritten offering of 2,750,498 shares, the gross proceeds from this offering are expected to be approximately $100 million. The proceeds intended to be used primarily to accelerate and support the enablement of Phase 3 trials for ANB032in Phase 2b development in atopic dermatitis, rosnilimab in Phase 2b development in rheumatoid arthritis and Phase 2 development in ulcerative colitis.